ILS employs six people, who will join the Mediq office in Helsinki. ILS is specialised in 

sales, marketing and servicing of hemostasis (bleeding disorders) and other critical care 

diagnostic products in Finland and in Estonia. 

Marc van Gelder, CEO Mediq: “ILS is a perfect fit as Mediq already has a strong offering of clinical laboratory products in Finland and the Baltics. Mediq is a committed partner for healthcare professionals. We continue to expand our specialised product offering for hospitals, in order to support our customers in providing the best possible care to their patients.”

Cristel Hodes, Director of Hodes: “We thought long and hard about this step. We want to retain our strong regional presence. That said, we also realise that we lack the economies of scale needed to meet the continually growing requirements of health insurers, which is why we’re joining Mediq CombiCare. They are a strong player in ostomy, incontinence and wound care, so we know for sure that, under the Mediq flag, our patients will still be in outstanding hands.” 

 

Marcel van den Broek, Executive Vice-President at Mediq: “We’re very pleased with this expansion in the Arnhem region. This acquisition fits in very well with our strategy for continued growth in the field of delivering medical devices for homecare. As such, we’d like to extend a warm welcome to our new colleagues.” 

Net sales − Down 3% to € 680.0 million; growth from acquisitions at D&I cancelled out by declining sales at Pharmacies Netherlands and Pharmacies Poland. 

EBITA from ordinary activities − Down 22% to € 29.0 million, mainly as a result of the declining sales from 

pharmaceuticals and the restructuring provision at Pharmacies Netherlands and higher corporate expenses. 

Net result − Amounted to € 10.0 million due to lower EBITA from ordinary activities and 

non-operational costs. 

Cash flow − Cash flow from operating activities of € 24.4 million. 

 

− Sales growth of 8% due to acquisitions; organic sales down by 1% following the transfer of biopharmaceuticals to the hospital budget (Netherlands). Excluding this effect, organic growth was 6%. 

− Positive trend in operating result for medical devices; lower operating result for pharmaceuticals (Netherlands). 

− EBITA margin from ordinary activities of 8.7%. 

− Acquisition of A-Med finalised; consolidated as of 1 December. 

− Lower sales and EBITA due to sharp fall in prices since beginning of 2012. 

− Restructuring of pharmacy and wholesaling activities; second tranche of restructuring provision recognised. 

− Sales down 10% as a result of a declining market since the beginning of 2012 due to statutory restrictions in patient discounts. 

− EBITA up, especially as result of higher gross margin and lower cost levels. 

AI Garden B.V. (the Offeror), a company ultimately indirectly controlled by funds advised and managed by Advent International Corporation (Advent), is pleased to announce that during the post closing acceptance period (na-aanmeldingstermijn) that ended on 12 February 2013 at 17:40 hours, Amsterdam time (the Post Closing Acceptance Period), 2,121,712 ordinary shares with a nominal value of EUR 0.25 each (the Shares) in the capital of Mediq N.V. (Mediq) were tendered for acceptance under the Offeror’s recommended all-cash public offer for all the issued and outstanding Shares (the Offer). These Shares represent approximately 3.6% of the total number of outstanding Shares and a value (at the increased Offer Price of EUR 14.00 per Share) of EUR 29,703,968.

Mediq respects his decision and loses a dedicated chairman. Sjoerd van Keulen has been a member of the Supervisory Board since April 2010. He became chairman on 6 September 2010. 

AI Garden B.V. (the Offeror), a company ultimately indirectly controlled by funds advised and managed by Advent International Corporation (Advent), is pleased to announce that it declares its recommended all-cash public offer (the Offer) for all the issued and outstanding ordinary shares with a nominal 

value of EUR 0.25 each (the Shares) in the capital of Mediq N.V. (Mediq) unconditional (doet gestand). 

The offer period, as extended by operation of law, ended today at 17:40 hours. Advent has informed that in total 96.1% of the Mediq shares have been tendered under the offer. At the latest on 1 February 2013, Advent will announce whether the offer for Mediq will be declared unconditional.

The offer price of € 14.00 is final and will not be increased further. The offer price represents an increase of € 0.75 compared to the initial offer, representing a bid premium of 61.8% compared to the closing share price as at 21 September 2012, the day before the initial announcement. 

 

On 4 January 2013, Advent extended the offer period, which initially expired that day, by two weeks until 18 January 2013 17:40 hours. At that point in time, in aggregate approximately 54% of the Mediq shares had been tendered. Pursuant to the Decree on Public Takeover Bids (Besluit openbare biedingen Wft) the offer period of the offer will, in connection with this price increase, be extended with seven business days from the moment of the increase. As a result thereof, the offer period will expire on 29 January 2013 17.40 hours. 

The initial offer period expired on 4 January 2013 at 17:40 hours CET. According to Advent, during the initial offer period in total around 54% of the shares has been tendered. The offer period has now been extended until 18 January 2013, 17:40 hours CET, such in accordance with the terms and conditions set out in the Offer Memorandum dated 8 November 2012.